BR0316192A - Método e composições para o tratamento da ansiedade - Google Patents

Método e composições para o tratamento da ansiedade

Info

Publication number
BR0316192A
BR0316192A BR0316192-7A BR0316192A BR0316192A BR 0316192 A BR0316192 A BR 0316192A BR 0316192 A BR0316192 A BR 0316192A BR 0316192 A BR0316192 A BR 0316192A
Authority
BR
Brazil
Prior art keywords
active ingredient
patient
pyridinyl
administered
compositions
Prior art date
Application number
BR0316192-7A
Other languages
English (en)
Inventor
Janet Codd
Bernard Beer
Original Assignee
Nascime Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascime Ltd filed Critical Nascime Ltd
Publication of BR0316192A publication Critical patent/BR0316192A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODO E COMPOSIçõES PARA O TRATAMENTO DA ANSIEDADE". Em um paciente através da administração oral, ao dito paciente, de uma dose diária do ingrediente ativo, 2-piridinil¢7-(4-piridinil)pirazolo¢1,5-a!-pirimidin-3-il!-metanona, ou seus sais farmaceuticamente aceitáveis, especialmente Ocinaplonin, em duas administrações divididas separadas, em que a primeira porção é administrada em uma forma de liberação lenta e a porção restante é administrada na forma de liberação imediata de modo a manter os níveis do sangue desse ingrediente ativo a níveis terapeuticamente relevantes para manter o efeito anti-ansiedade no paciente durante os períodos entre as administrações desse ingrediente ativo, bem como as composições farmacêuticas que contêm esse ingrediente ativo para a administração em relação ao método acima.
BR0316192-7A 2002-12-04 2003-11-25 Método e composições para o tratamento da ansiedade BR0316192A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43074002P 2002-12-04 2002-12-04
PCT/US2003/037714 WO2004050019A2 (en) 2002-12-04 2003-11-25 Method and compositions for treating anxiety

Publications (1)

Publication Number Publication Date
BR0316192A true BR0316192A (pt) 2005-10-11

Family

ID=32469522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316192-7A BR0316192A (pt) 2002-12-04 2003-11-25 Método e composições para o tratamento da ansiedade

Country Status (12)

Country Link
US (1) US20040192706A1 (pt)
EP (1) EP1581230A2 (pt)
JP (1) JP2006509789A (pt)
KR (1) KR20050085386A (pt)
CN (1) CN1720048A (pt)
AU (1) AU2003297559A1 (pt)
BR (1) BR0316192A (pt)
CA (1) CA2507609A1 (pt)
NO (1) NO20053310L (pt)
PL (1) PL377357A1 (pt)
RU (1) RU2005120749A (pt)
WO (1) WO2004050019A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529142A (ja) * 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration

Also Published As

Publication number Publication date
WO2004050019A9 (en) 2012-03-22
EP1581230A2 (en) 2005-10-05
PL377357A1 (pl) 2006-02-06
WO2004050019A3 (en) 2004-08-12
CN1720048A (zh) 2006-01-11
NO20053310D0 (no) 2005-07-04
CA2507609A1 (en) 2004-06-17
NO20053310L (no) 2005-08-29
KR20050085386A (ko) 2005-08-29
JP2006509789A (ja) 2006-03-23
AU2003297559A1 (en) 2004-06-23
WO2004050019A2 (en) 2004-06-17
US20040192706A1 (en) 2004-09-30
RU2005120749A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
NO20080244L (no) Doseringsstyring for prasugrel
ATE305469T1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklyl midverbindungen
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
PT1069900E (pt) Novos tratamentos para disturbios nervosos
DE602007014193D1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
BR0311747A (pt) Composição farmacêutica, forma de dose simples ou de múltiplas doses da composição, kit, e, método para tratar doença
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
US5945119A (en) Therapeutic preparations containing caesium ions
BR0316192A (pt) Método e composições para o tratamento da ansiedade
ATE298240T1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
JP2001316293A5 (pt)
BR9810214A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, para tratar ou reduzir o risco de doença inflamatória e de dor em uma pessoa sofrendo de ou sob risco de dita doença, de tratamento, e para a preparação de um composto
BR9808546A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto
RU2021106904A (ru) КОМБИНАЦИИ ИНГИБИТОРОВ TGFβ И ИНГИБИТОРОВ CDK ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
Mehta et al. Xanthinol nicotinate induced bullous drug eruption
JP2004026810A (ja) 鼻炎用組成物
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]